Printer Friendly

COMPANY INFORMATION
Oncothyreon Inc. 2601 Fourth Ave, Suite 500 Seattle, WA, United States 98121 Tel: (206) 801-2100 Fax: (206) 801-2101 Contact Name Investor Relations Industry Biotechnology		Key Executives Robert L. Kirkman, CEO Shashi K. Karan, contr. Researches and develops synthetic vaccines and targeted small molecules for the treatment of cancer. The company's cancer vaccines are designed to stimulate an individual's immune system to recognize cancer cells and control the growth and spread of cancers and its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The company's lead vaccine product candidate is Stimuvax®, a cancer vaccine for non-small cell lung cancer (Phase III) which has been licensed to Merck KGaA. Targeted small molecule product candidates include PX-12 (Phase II), PX-478 (Phase I) and PX-866 (pre-clinical).
FP ADVISOR COVERAGE Oncothyreon Inc. • FP Corporate Surveys • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF OCT 22/09 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta Nasdaq/ONTY $4.53 $8.28 $1.08 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) n.a. 10.80 US$0.39 Sept. 30/09 n.a. n.a. n.a. $116,248
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08A 12m Dec. 31/07A 12m Dec. 31/06 US$000s US$000s $000s Operating revenue 39,998 3,798 4,514 Net income 7,125 (20,340) (17,822) Total assets 24,971 36,218 79,099 US$ US$ $ Earnings per share* 0.37 (1.04) (1.14) % % % Return on equity 43.53 (59.58) (43.75)   * Common A Reported in accordance with U.S. GAAP
TRAILING 12-MONTH VALUES Periods ended: June 30/09A June 30/08A US$000s US$000s Operating revenue 36,861 6,286 Net income 8,351 (21,690) US$ US$ Earnings per share 0.45 (1.15)   A Reported in accordance with U.S. GAAP

COMPANY NEWS

Results for 'Oncothyreon Inc.' from past 30 days: No hits. (Links are to articles.)